Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease

Andrea Caddeo, Stefano Romeo

Clin Mol Hepatol. 2025;31(Suppl):S76-S93. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0438

View: 3295 Download: 440 Web of Science: 5 Crossref: 7

Correspondence

The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):e183-e185. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0152

View: 625 Download: 13 Crossref: 1

Letter to the Editor

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes

Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen

Clin Mol Hepatol. 2025;31(1):e35-e38. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0719

View: 1204 Download: 67 Web of Science: 1 Crossref: 1

The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread

Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang

Clin Mol Hepatol. 2025;31(1):e25-e26. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0993

View: 968 Download: 40 Crossref: 1

Original Article

Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian

Clin Mol Hepatol. 2025;31(1):179-195. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0359

View: 1833 Download: 162 Web of Science: 2 Crossref: 2

Review

Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations

Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim

Clin Mol Hepatol. 2025;31(1):74-89. Published online October 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0631

View: 3762 Download: 373 Web of Science: 8 Crossref: 12

Original Article

Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis

Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun

Clin Mol Hepatol. 2024;30(Suppl):S147-S158. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0330

View: 2585 Download: 141 Web of Science: 4 Crossref: 5

Correspondence

Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Vy H. Nguyen, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(4):1000-1001. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0611

View: 1241 Download: 40

Letter to the Editor

Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li

Clin Mol Hepatol. 2024;30(4):974-977. Published online July 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0417

View: 1982 Download: 81 Crossref: 1

Correspondence

In response to: Steatotic liver disease-know your enemies

Michael H. Le, Linda Henry, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):284-286. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0108

View: 2583 Download: 49

Original Article

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):235-246. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0485

View: 7967 Download: 320 Web of Science: 25 Crossref: 30

Letter to the Editor

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon

Clin Mol Hepatol. 2024;30(1):118-120. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0472

View: 3027 Download: 67 Web of Science: 2 Crossref: 1

Review

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0392

View: 8351 Download: 288 Web of Science: 25 Crossref: 31

Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management

Anja Geerts, Sander Lefere

Clin Mol Hepatol. 2023;29(Suppl):S276-S285. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0373

View: 5277 Download: 158 Web of Science: 12 Crossref: 14

Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease

Georg Semmler, Christian Datz, Michael Trauner

Clin Mol Hepatol. 2023;29(Suppl):S244-S260. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0364

View: 8699 Download: 363 Web of Science: 21 Crossref: 25

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0348

View: 6350 Download: 351 Web of Science: 28 Crossref: 28

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 6844 Download: 277 Web of Science: 24 Crossref: 22

Interaction between sarcopenia and nonalcoholic fatty liver disease

Sae Kyung Joo, Won Kim

Clin Mol Hepatol. 2023;29(Suppl):S68-S78. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0358

View: 7659 Download: 342 Web of Science: 41 Crossref: 42

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 26017 Download: 1,474 Web of Science: 203 Crossref: 210

Letter to the Editor

Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh

Clin Mol Hepatol. 2023;29(4):1046-1047. Published online August 22, 2023

DOI: https://doi.org/10.3350/cmh.2023.0268

View: 2699 Download: 53 Web of Science: 1 Crossref: 1

Editorial

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

Ming-Lun Yeh, Ming-Lung Yu

Clin Mol Hepatol. 2023;29(4):969-972. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0359

View: 3872 Download: 187 Web of Science: 11 Crossref: 13

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

Xianhua Mao, Lung Yi Mak, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(3):690-692. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0173

View: 3181 Download: 112 Web of Science: 2 Crossref: 2

Original Article

Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma

Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):453-464. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0450

View: 4948 Download: 137 Web of Science: 6 Crossref: 6

Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease

Kathryn Jane Waller, Hajar Saihi, Wenhao Li, James Hallimond Brindley, Anja De Jong, Wing-kin Syn, Conrad Bessant, William Alazawi

Clin Mol Hepatol. 2023;29(2):417-432. Published online November 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0205

View: 7344 Download: 217 Web of Science: 4 Crossref: 6

Editorial

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 4177 Download: 95 Web of Science: 2 Crossref: 1

Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed

Philipp Kasper, Münevver Demir, Hans-Michael Steffen

Clin Mol Hepatol. 2023;29(2):390-393. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0059

View: 3940 Download: 69 Web of Science: 2 Crossref: 2

Original Article

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang

Clin Mol Hepatol. 2019;25(1):52-64. Published online October 23, 2018

DOI: https://doi.org/10.3350/cmh.2018.0040

View: 10002 Download: 362 Web of Science: 86 Crossref: 83

Review

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs

Stephen Caldwell

Clin Mol Hepatol. 2017;23(2):103-108. Published online May 10, 2017

DOI: https://doi.org/10.3350/cmh.2017.0103

View: 13903 Download: 486 Web of Science: 36 Crossref: 34

Original Article

Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease

Min-Sun Kwak, Donghee Kim, Goh Eun Chung, Seung Joo Kang, Min Jung Park, Yoon Jun Kim, Jung-Hwan Yoon, Hyo-Suk Lee

Clin Mol Hepatol. 2012;18(4):383-390. Published online December 21, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.4.383

View: 18000 Download: 134 Crossref: 91

5

Nonalcoholic Steatohepatitis

So-Young Jin

Clin Mol Hepatol. 2006;12(3):455-459. Published online January 1, 2000

View: 2885 Download: 21

1 | 2 |

Viewed By 10943	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7654	MAFLD: How is it different from NAFLD?
Viewed By 5548	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5001	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 4907	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 342	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search